EUR/USD 1.15977
-0.192%
Gold 4062.04
-0.612%
Oil 59.895
0.246%
USD/JPY 155.093
0.366%
GBP/USD 1.31674
-0.001%
GBP/JPY 204.222
0.366%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
The UK Financial Conduct Authority will submit a formal response this week regarding matters related to bond market data providers.Five sources say Chevron (CVX.N) is exploring the option of acquiring overseas assets of Russias Lukoil.Google: Will invest in building two new connectivity hubs across the Indian Ocean region.On November 17th, Bank of England Monetary Policy Committee member Mann warned that businesses are still reacting to high inflation, indicating that policymakers are far from relaxing their efforts to curb price pressures in the economy. Mann stated on Monday that "there is still work to be done" to bring inflation back to the 2% target. She noted that there are signs that businesses remain highly focused on inflation when formulating their pricing strategies for the coming year. Mann pointed out, "As a policymaker, this means there are still upside risks to the intrinsic drivers of inflation. In a high-inflation environment, there is a price asymmetry: businesses are more likely to raise prices than lower them." As one of the most hawkish members of the Monetary Policy Committee, Mann has consistently advocated maintaining tight interest rates to prevent inflation from solidifying above the target.A U.S. appeals court is expected to hear arguments from families on Monday who are urging the court to reinstate more than 500 lawsuits against Kenvue, the maker of Tylenol, after the Trump administration publicly promoted claims that the widely used painkiller was linked to childhood autism.

Novavax Reduces Its Full-year Revenue Forecast Due to Sluggish Demand

Haiden Holmes

Nov 09, 2022 15:55

52.png


Novavax (NASDAQ:NVAX) decreased its full-year revenue guidance for the second time in three months on Tuesday as a result of a global supply glut in COVID-19 vaccine and declining demand.


The company now expects its annual revenues to fall within the lower half of its earlier forecast range of $2 billion to $2.3 billion.


Novavax reduced its revenue forecast for the year in August, since the business did not expect to sell any additional COVID-19 vaccine in the United States this year.


Filip Dubovsky, the chief medical officer of Novavax, stated on a conference call with investors that the company is "moving forward" with the development of a vaccine against Omicron sub variants BQ.1 and BQ.1.1, which would also be formulated as a bivalent vaccination with another coronavirus strain.


Dubovsky noted that Novavax intends to get the vaccine ready by the second quarter of 2019 in time for an expected surge in cases in the southern hemisphere.


Novavax stated Tuesday morning that its COVID-19 vaccine has been modified for the Omicron BA.


In advanced study, one variant generated a substantial immune response at the fourth dose, meeting the strain swift's main purpose.


The shares of the Maryland-based firm surged by nearly 1 percent in afternoon trading after the company reported third-quarter revenues that were above analyst projections.


Last week, Pfizer Inc. (NYSE:PFE) increased its annual COVID vaccination sales projection. After the government ceases buying doses and sales move to the private sector, the company intends to almost double the price of the vaccine injection in the United States in order to combat declining sales.


Even though more than 640 million COVID-19 doses have been distributed in the United States, just 43,540 Novavax vaccines have been delivered as of November 2, according to the most current government figures.


In October, the U.S. Food and Drug Administration authorized the COVID-19 vaccine as a booster for adults, in addition to its existing clearance as a primary two-shot regimen for those 12 and older.

Suggestion